Caitlin Costello, MD
Associate Clinical Professor of Medicine
UC San Diego Health
Moores Cancer Center
Division of Blood and Marrow Transplant
La Jolla, California
Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program
HonorHealth Research Institute
Adjunct Professor, College of Health Solutions
Arizona State University
Phoenix, Arizona

Program Description

This Phone-a-Friend™ activity features 2 MM experts discussing clinical evidence for different bispecific antibody therapies for RRMM, practical considerations for implementing treatment, and how to monitor and manage adverse events.  

Target Audience

This activity is intended for hematologic oncology clinicians, including physicians, fellows, nurse practitioners (NPs), nurses, and physician associates (PAs), in both the academic and the community setting.

Educational Objectives

  1. Describe the efficacy and safety profiles of US FDA-approved bispecific antibody therapy for the treatment of relapsed or refractory multiple myeloma (RRMM)
  2. Incorporate FDA-approved bispecific antibody therapy into treatment regimens for patients with RRMM

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 0.25 contact hours, including 0.0 pharmacotherapeutic contact hours, is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Relevant Financial Relationships

Integritas Communications and Global Education Group adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Caitlin Costello, MD 
  • Consultant: Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Karyopharm, Pfizer Inc., and Regeneron
Joseph Mikhael, MD, MEd, FRCPC, FACP
  • Consultant: Amgen, Bristol Myers Squibb, Janssen Pharmaceuticals, and Sanofi
The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For information about the accreditation (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

Global Contact Information

For information about the accreditation (ANCC) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Begin Activity
available resources
linked resources
Suggested Reading

Making the Call in Relapsed or Refractory Multiple Myeloma

Incorporating Bispecific Antibody Therapy Into Practice